[1]
|
Kong, J., Li, L., Yuan, H., et al. (2023) In Silico Discovery of Potential Sodium—Glucose Cotransporter-2 Inhibitors from Natural Products for Treatment of Heart Failure via Molecular Docking and Molecular Dynamics Simulation Ap-proach. Journal of Biomolecular Structure and Dynamics, 41, 8109-8120.
https://doi.org/10.1080/07391102.2022.2130983
|
[2]
|
Tuttle, K.R. (2023) Digging Deep into Cells to Find Mecha-nisms of Kidney Protection by SGLT2 Inhibitors. Journal of Clinical Investigation, 133, E167700. https://doi.org/10.1172/JCI167700
|
[3]
|
Wheeler, D.C., StefÁNsson, B.V., Jongs, N., et al. (2021) Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease: A Prespecified Analysis from the DAPA-CKD Trial. The Lancet Diabetes & Endocrinology, 9, 22-31.
https://doi.org/10.1016/S2213-8587(20)30369-7
|
[4]
|
Zhou, Y., Wang, F., Wen, F., et al. (2023) The SGLT2i-Mediated Regulation of Cardiovascular and Safety Outcomes among Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. https://doi.org/10.21203/rs.3.rs-2453557/v1
|
[5]
|
刘姗姗, 赵璨, 罗力亚. 达格列净治疗老年2型糖尿病并心力衰竭患者的临床疗效及其对心功能的影响[J]. 实用心脑肺血管病杂志, 2022, 30(3): 107-111.
|
[6]
|
余蓓蕾, 姜玲, 李喆, 等. 肾小球滤过率对急慢性肾脏病患者溶质及电解质肾脏排泄分数的影响[J]. 肾脏病与透析肾移植杂志, 2023, 32(1): 1-7.
|
[7]
|
Li, Y., Ning, Y., Shen, B., et al. (2023) Temporal Trends in Prevalence and Mortality for Chronic Kidney Disease in China from 1990 to 2019: An Analysis of the Global Burden of Disease Study 2019. Clinical Kidney Journal, 16, 312-321. https://doi.org/10.1093/ckj/sfac218
|
[8]
|
Khadilkar, A., Oza, C. and Mondkar, S.A. (2023) Insulin Resistance in Adolescents and Youth with Type 1 Diabetes: A Review of Problems and Solutions. Clinical Medi-cine Insights: Endocrinology and Diabetes, 16.
https://doi.org/10.1177/11795514231206730
|
[9]
|
王丽, 苏钢, 洪娟, 等. 达格列净对早期糖尿病肾病的疗效观察[J]. 中国医师进修杂志, 2023, 46(10): 930-933.
https://doi.org/10.3760/cma.j.cn115455-20220425-00355
|
[10]
|
储帆, 梁伟, 刘子康, 等. 达格列净治疗不同肾功能状态糖尿病肾脏疾病患者水肿的疗效与安全性分析[J]. 临床肾脏病杂志, 2023, 23(7): 575-584.
|
[11]
|
Groop, P.H., Dandona, P., Phillip, M., et al. (2020) Effect of Dapagliflozin as an Adjunct to Insulin over 52 Weeks in Individu-als with Type 1 Diabetes: Post-Hoc Renal Analysis of the DEPICT Randomised Controlled Trials. The Lancet Diabetes & Endocrinology, 8, 845-854. https://doi.org/10.1016/S2213-8587(20)30280-1
|
[12]
|
Mathieu, C., Rudofsky, G., Phillip, M., et al. (2020) Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (The DEPICT-2 Study): 52-Week Results from a Randomized Controlled Trial. Diabetes, Obesity and Metabo-lism, 22, 1516-1526. https://doi.org/10.1111/dom.14060
|
[13]
|
Janković, A., Dimković, N., Todorov-Sakić, V., et al. (2023) Presence of Non-Diabetic Kidney Diseases in Biopsy Specimens of Diabetic Patients’ Single Center Experience. International Journal of Molecular Sciences, 24, Article 14759. https://doi.org/10.3390/ijms241914759
|
[14]
|
Cherney, D.Z.I., Dekkers, C.C.J., Barbour, S.J., et al. (2020) Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised, Double-Blind, Crossover Trial. The Lancet Diabetes & Endocrinology, 8, 582-593. https://doi.org/10.1016/S2213-8587(20)30162-5
|
[15]
|
Gohda, T. and Murakoshi, M. (2022) Sodium-Glucose Co-transporter-2 Inhibitors—Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. International Journal of Molecular Sciences, 23, Article 13749.
https://doi.org/10.3390/ijms232213749
|
[16]
|
Rossing, P., Inzucchi, S.E., Vart, P., et al. (2022) Dapagliflozin and New-Onset Type 2 Diabetes in Patients with Chronic Kidney Disease or Heart Failure: Pooled Analysis of the DAPA-CKD and DAPA-HF Trials. The Lancet Diabetes & Endocrinology, 10, 24-34. https://doi.org/10.1016/S2213-8587(21)00295-3
|
[17]
|
Schechter, M., Jongs, N., Chertow, G, M., et al. (2023) Ef-fects of Dapagliflozin on Hospitalizations in Patients with Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD. Annals of Internal Medicine, 176, 59-66.
https://doi.org/10.7326/M22-2115
|
[18]
|
McEwan, P., Darlington, O., Miller, R., et al. (2022) Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clinical Jour-nal of the American Society of Nephrology, 17, 1730-1741. https://doi.org/10.2215/CJN.03790322
|
[19]
|
Wheeler, D.C., Jongs, N., Stefansson, B.V., et al. (2022) Safety and Efficacy of Dapagliflozin in Patients with Focal Segmental Glomerulosclerosis: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kid-ney Disease (DAPA-CKD) Trial. Nephrology Dialysis Transplantation, 37, 1647-1656.
https://doi.org/10.1093/ndt/gfab335
|
[20]
|
Heerspink, H.J.L., Cherney, D., Postmus, D., et al. (2022) A Pre-Specified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) Randomized Controlled Trial on the Incidence of Abrupt Declines in Kidney Function. Kidney Interna-tional, 101, 174-184. https://doi.org/10.1016/j.kint.2021.09.005
|
[21]
|
Chertow, G.M., Correa-Rotter, R., Vart, P., et al. (2023) Effects of Dapagliflozin in Chronic Kidney Disease, with and without Other Cardiovascular Medications: DAPA-CKD Trial. Journal of the American Heart Association, 12, e028739. https://doi.org/10.1161/JAHA.122.028739
|
[22]
|
张青青, 刘珊珊, 王英惠, 等. 达格列净治疗慢性肾脏病的研究进展[J]. 山东第一医科大学(山东省医学科学院)学报, 2022, 43(5): 388-392. https://Doi.Org/10.3969/J.Issn.2097-0005.2022.05.014
|
[23]
|
Bonnet, F. and Scheen, A, J. (2018) Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complica-tions and Cardiovascular Disease. Diabetes & Metabolism, 44, 457-464. https://doi.org/10.1016/j.diabet.2018.09.005
|
[24]
|
Huang, F., Zhao, Y., Wang, Q., et al. (2019) Dapagliflozin At-tenuates Renal Tubulointerstitial Fibrosis Associated with Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. Frontiers in Endocrinology, 10, Article 441.
https://doi.org/10.3389/fendo.2019.00441
|
[25]
|
Hodrea, J., Balogh, D.B., Hosszu, A., et al. (2020) Reduced O-GlcNAcylation and Tubular Hypoxia Contribute to the Antifibrotic Effect of SGLT2 Inhibitor Dapagliflozin in the Diabetic Kidney. American Journal of Physiology-Renal Physiology, 318, F1017-F1029. https://doi.org/10.1152/ajprenal.00021.2020
|
[26]
|
Shibusawa, R., Yamada, E. and Okada, S. (2019) Dapagliflozin Rescues Endoplasmic Reticulum Stress-Mediated Cell Death. Scientific Reports, 9, Article No. 9887. https://doi.org/10.1038/s41598-019-46402-6
|
[27]
|
Elkazzaz, S.K., Khodeer, D.M., El Fayoumi, H.M. and Moustafa, Y.M. (2021) Role of Sodium Glucose Cotransporter Type 2 Inhibitors Dapagliflozin on Diabetic Nephropathy in Rats; Inflammation, Angiogenesis and Apoptosis. Life Sciences, 280, Article ID: 119018. https://doi.org/10.1016/j.lfs.2021.119018
|
[28]
|
Jaikumkao, K., Pongchaidecha, A., Chueakula, N., et al. (2018) Dapagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, Slows the Progression of Renal Complications through the Suppression of Renal Inflammation, Endoplasmic Reticulum Stress and Apoptosis in Prediabetic Rats. Diabetes, Obesity and Metabolism, 20, 2617-2626.
https://doi.org/10.1111/dom.13441
|
[29]
|
Baer, P.C., Koch, B., Freitag, J., et al. (2020) No Cytotoxic and Inflam-matory Effects of Empagliflozin and Dapagliflozin on Primary Renal Proximal Tubular Epithelial Cells under Diabetic Conditions in Vitro. International Journal of Molecular Sciences, 21, Article 391. https://doi.org/10.3390/ijms21020391
|
[30]
|
Lupsa, B.C. and Inzucchi, S.E. (2018) Use of SGLT2 Inhibitors in Type 2 Diabetes: Weighing the Risks and Benefits. Diabetologia, 61, 2118-2125. https://doi.org/10.1007/s00125-018-4663-6
|
[31]
|
曹丹, 张桂红, 赵钰. 达格列净在早期2型糖尿病肾病中的应用及对肾功能的影响分析[J]. 糖尿病新世界, 2023, 26(8): 106-108.
|
[32]
|
Hallow, K.M., Boulton, D.W., Penland, R.C., et al. (2020) Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. Journal of Pharmacology and Experimental Therapeu-tics, 375, 76-91. https://doi.org/10.1124/jpet.120.000040
|
[33]
|
Van Bommel, E.J.M., Muskiet, M.H.A., Van Baar, M.J.B., et al. (2020) The Renal Hemodynamic Effects of the SGLT2 Inhibitor Dapagliflozin Are Caused by Post-Glomerular Vasodilatation Rather than Pre-Glomerular Vasoconstriction in Metformin-Treated Patients with Type 2 Diabetes in the Randomized, Double-Blind RED Trial. Kidney International, 97, 202-212. https://doi.org/10.1016/j.kint.2019.09.013
|